HIBISKUS BIOPHARMA
Hibiskus Biopharma is an early-stage pharmaceutical venture pursuing the development of small-molecule cancer therapy, TIR-199. TIR-199 is a potent proteasome inhibitor from the syrbactin natural product family. It was discovered by the company’s founders, Profs. Pirrung and Bachmann of the University of California, Riverside (UCR), and Michigan State University (MSU), respectively. UCR holds multiple patents related to the production of TIR-199 and its use in treating cancers and immune disorders.
HIBISKUS BIOPHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Kalamazoo, Michigan, United States
Country:
United States
Website Url:
http://www.hibiskusbio.com
Status:
Active
Technology used in webpage:
Domain Not Resolving Gravatar Profiles
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Biohelix
Biohelix is to improve the quality of healthcare through the development of simple molecular diagnostic tests.
Mistral Pharma
Mistral Pharma, Inc. is a development stage pharmaceutical product development and drug delivery company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
